|Bid||125.10 x 1000|
|Ask||125.15 x 900|
|Day's Range||124.62 - 126.12|
|52 Week Range||78.90 - 130.08|
|Beta (3Y Monthly)||0.62|
|PE Ratio (TTM)||44.32|
|Earnings Date||Oct 30, 2019 - Nov 4, 2019|
|Forward Dividend & Yield||0.66 (0.53%)|
|1y Target Est||131.58|
Biotech and pharmaceutical company stocks got no traction this week from the proposed $2 billion takeover of Alder Biopharmaceuticals or a "largely symbolic" House plan to slash drug prices.
Zoetis Inc. (ZTS) today announced that the European Commission has granted marketing authorisation for Simparica Trio™ (sarolaner/moxidectin/pyrantel) chewable tablets, a once-monthly triple combination antiparasitic medication for dogs with, or at risk from, mixed external and internal parasitic infestations. The granting of the marketing authorisation follows a positive opinion adopted by the Committee for Medicinal Products for Veterinary Use on July 18, 2019.
Lescault, 43, who enrolled Moose in a clinical trial of an experimental drug designed to help his immune system fight his cancer, represents the type of pet lover that has spurred animal health companies around the globe to invest in developing complex new treatments previously reserved for humans. Biotechnology, which produces medicines from living cells, revolutionized the drug industry more than a quarter century ago with breakthrough medicines at prices that now run as high as hundreds of thousands of dollars a year.
Successful innovation resulting in new drug approvals, important advances in clinical studies, frequent collaborations and M&A activity have kept small drugmakers afloat in a competitive market.
Zoetis (ZTS) is the largest pure-play animal health and vaccine company and is the market leader in revenue. We believe that the industry has solid growth potential and that Zoetis will be able to optimize its leadership position, explains Jasper Hellweg, analyst with Argus Research.
Animal-health firm Zoetis could launch a blockbuster, an analyst said after the pharmaceutical company posted strong results for its heartworm medicine. But Zoetis stock slid Tuesday.
The ProShares Pet Care ETF (CBOE: PAWZ), the first and still the only dedicated pet care ETF, has plenty of favorable tailwinds. Another one may be arriving in the form of regulatory approval of Simparica ...
The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs on Sept. 9.) ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD ...
Triple combination product contains sarolaner, moxidectin and pyrantel
Zoetis, the largest animal-health company, received an upgrade on Monday ahead of the expected regulatory approval of Simparica Trio, an oral canine drug that is expected to generate big sales.
Zoetis Inc. (ZTS) will participate in the Bank of America Merrill Lynch Global Healthcare Conference on Thursday, Sept. 19, 2019, in London, England. Clint Lewis, Executive Vice President and Group President, International Operations, Commercial Development, Global Genetics, Aquatic Health and Human Medical Diagnostics, will represent the company and respond to questions from analysts.
Pharmaceutical stocks slipped a single-digit percentage in the first eight months of 2019, well below their gain for 2018. Still, there are standout companies among the industry group.
IDEXX Laboratories and Zoetis Inc. appear ready to trade higher, offering stable opportunities as the dog-eat-dog trade war lingers on.